Arvinas (ARVN) Gains from Investment Securities (2017 - 2025)
Arvinas (ARVN) recorded quarterly Gains from Investment Securities of -$1.5 million in Q2 2025, down 200.0% quarter-over-quarter from $1.5 million in Q1 2025, and down 600.0% on a YoY basis from $300000.0 in Q2 2024.
Arvinas (ARVN) Gains from Investment Securities (2017 - 2025) Analysis & Trends
Arvinas' Gains from Investment Securities history runs 9 years deep, the most recent figure standing at -$1.5 million for Q2 2025.
- In Q2 2025, Gains from Investment Securities fell 600.0% year-over-year to -$1.5 million; the TTM figure through Sep 2025 stood at -$4.2 million (up 44.0% YoY), while the FY2024 annual figure was -$2.6 million, changed N/A from the prior year.
- Gains from Investment Securities was -$1.5 million for Q2 2025 at Arvinas, down from $1.5 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $9.0 million in Q2 2023 to a low of -$9.1 million in Q4 2023.
- Historically, Gains from Investment Securities has averaged $807173.4 across 5 years, with a median of $750000.0 in 2024.
- The sharpest annual moves came in 2022 and 2025: Gains from Investment Securities surged 446.61% in 2022, then tumbled 600.0% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at $1.5 million in 2021, then soared by 102.45% to $3.0 million in 2022, then slumped by 403.33% to -$9.1 million in 2023, then jumped by 53.85% to -$4.2 million in 2024, then jumped by 64.29% to -$1.5 million in 2025.
- The last three Gains from Investment Securities figures came in at -$1.5 million (Q2 2025), $1.5 million (Q1 2025), and -$4.2 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -1.50 Mn |
| Jun 30, 2025 | -1.50 Mn |
| Mar 31, 2025 | 1.50 Mn |
| Mar 31, 2025 | 1.50 Mn |
| Dec 31, 2024 | -4.20 Mn |
| Dec 31, 2024 | -4.20 Mn |
| Sep 30, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 300,000.00 |
| Mar 31, 2024 | 1.20 Mn |
| Mar 31, 2024 | 1.20 Mn |
| Dec 31, 2023 | -9.10 Mn |
| Dec 31, 2023 | -9.10 Mn |
| Sep 30, 2023 | 100,000.00 |
| Sep 30, 2023 | 100,000.00 |
| Jun 30, 2023 | 9.00 Mn |
| Jun 30, 2023 | 9.00 Mn |
| Dec 31, 2022 | 3.00 Mn |
| Dec 31, 2022 | 3.00 Mn |